BlueLinx (BXC) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
The annual meeting is scheduled for May 15, 2025, at the company’s headquarters, with voting on director elections, auditor ratification, and executive compensation approval.
Stockholders of record as of March 18, 2025, are eligible to vote, with a majority quorum required.
Proxy materials, including the annual report and proxy statement, are available online and by mail.
Voting matters and shareholder proposals
Stockholders will vote to elect eight directors, ratify Ernst & Young LLP as the independent auditor for fiscal 2025, and approve a non-binding advisory resolution on executive compensation.
The board recommends voting FOR all director nominees and FOR both proposals.
No other business is expected, but proxies allow for discretionary voting on unforeseen matters.
Board of directors and corporate governance
Eight directors are nominated for re-election; one current director is retiring, and a search firm is engaged to fill the vacancy.
The board is majority independent, with separate CEO and non-executive chairman roles.
Three standing committees: Audit, Human Capital and Compensation, and Nominating and Governance, all with independent members.
Director compensation includes cash and equity, with stock ownership guidelines requiring directors to hold shares equal to five times the cash retainer.
Latest events from BlueLinx
- Flat sales, specialty growth, and strong liquidity amid market headwinds and margin pressure.BXC
Q4 202525 Feb 2026 - Q2 2024 net sales fell 5.8%-6%, but specialty margins and liquidity remained strong.BXC
Q2 20242 Feb 2026 - Net sales fell 7.7%-8%, but strong cash flow and liquidity supported capital returns.BXC
Q3 202417 Jan 2026 - 2024 net sales hit $3.0B, with strong margins, liquidity, and $45M in share repurchases.BXC
Q4 202423 Dec 2025 - Q1 2025 net sales fell 2.3% as margins compressed, but liquidity and repurchases stayed strong.BXC
Q1 202528 Nov 2025 - Q2 2025 sales rose 2%, but net income and margins declined amid higher costs and price deflation.BXC
Q2 202516 Nov 2025 - Q3 sales up 0.2%, margins down, specialty leads, Disdero deal, and strong liquidity.BXC
Q3 202513 Nov 2025